X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2820) 2820
Patent (94) 94
Book Chapter (81) 81
Book / eBook (63) 63
Conference Proceeding (52) 52
Publication (40) 40
Newspaper Article (34) 34
Book Review (24) 24
Magazine Article (13) 13
Web Resource (10) 10
Dissertation (4) 4
Report (4) 4
Government Document (3) 3
Paper (3) 3
Archival Material (1) 1
Microfilm (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1219) 1219
female (724) 724
male (674) 674
index medicus (539) 539
middle aged (491) 491
adult (414) 414
aged (407) 407
hematology (371) 371
peripheral vascular disease (323) 323
animals (298) 298
medicine, general & internal (244) 244
risk factors (224) 224
venous thromboembolism (194) 194
thrombosis (189) 189
adolescent (178) 178
thromboembolism (172) 172
cardiac & cardiovascular systems (166) 166
prospective studies (166) 166
pulmonary embolism (165) 165
treatment outcome (163) 163
deep-vein thrombosis (155) 155
aged, 80 and over (151) 151
diagnosis (146) 146
venous thrombosis (146) 146
anticoagulants - therapeutic use (142) 142
time factors (141) 141
research (138) 138
anticoagulants (131) 131
risk (127) 127
analysis (122) 122
mortality (122) 122
follow-up studies (119) 119
prevention (112) 112
cancer (111) 111
child (101) 101
health aspects (98) 98
care and treatment (97) 97
mice (97) 97
management (96) 96
pulmonary embolism - diagnosis (96) 96
recurrence (93) 93
abridged index medicus (88) 88
surgery (87) 87
predictive value of tests (83) 83
anticoagulants - adverse effects (81) 81
hemorrhage - chemically induced (81) 81
pregnancy (81) 81
drug therapy (79) 79
rats (79) 79
retrospective studies (76) 76
prevalence (75) 75
cohort studies (74) 74
molecular-weight heparin (74) 74
double-blind method (72) 72
mutation (72) 72
prognosis (72) 72
pulmonary-embolism (71) 71
therapy (71) 71
anticoagulants - administration & dosage (70) 70
oncology (70) 70
studies (69) 69
d-dimer (66) 66
incidence (66) 66
warfarin (66) 66
disease (65) 65
sensitivity and specificity (64) 64
young adult (64) 64
coagulation (62) 62
fibrin fibrinogen degradation products - analysis (62) 62
heparin (60) 60
risk assessment (59) 59
viruses (59) 59
gastroenterology & hepatology (57) 57
pediatrics (57) 57
virology (57) 57
ultrasonography (56) 56
usage (56) 56
child, preschool (55) 55
netherlands (54) 54
research article (52) 52
electricity (51) 51
vitamin k - antagonists & inhibitors (51) 51
angiography (50) 50
biochemistry & molecular biology (50) 50
heparin - therapeutic use (50) 50
medical research (49) 49
patients (49) 49
reproducibility of results (49) 49
microbiology (48) 48
physiological aspects (48) 48
algorithms (47) 47
complications (47) 47
probability (47) 47
proteins (47) 47
randomized controlled trials as topic (47) 47
risk-factors (47) 47
venous thrombosis - drug therapy (47) 47
fungi (46) 46
heparin, low-molecular-weight - therapeutic use (46) 46
trial (46) 46
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (11) 11
Robarts - Stacks (10) 10
Gerstein Science - Stacks (5) 5
UTL at Downsview - May be requested (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Earth Sciences (Noranda) - Stacks (3) 3
Royal Ontario Museum - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Criminology - Stacks (1) 1
Earth Sciences (Noranda) - Oversize (1) 1
Knox College (Caven) - Reference (1) 1
Media Commons - Microtexts (1) 1
OISE - Microfiche (1) 1
OISE - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Regis College - Reference (1) 1
Royal Ontario Museum - Periodical Stacks (1) 1
Royal Ontario Museum - Rare Book (1) 1
Royal Ontario Museum - Rare Oversize (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
Trinity College (John W Graham) - Reference (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University Emmanuel College - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3131) 3131
Dutch (58) 58
German (35) 35
French (34) 34
Portuguese (8) 8
Russian (7) 7
Spanish (6) 6
Chinese (4) 4
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature chemistry, ISSN 1755-4349, 2017, Volume 9, Issue 7, pp. 629 - 634
C-H bonds are ubiquitous structural units of organic molecules. Although these bonds are generally considered to be chemically inert, the recent emergence... 
INTRAMOLECULAR C(SP)-H AMINATION | MONOOXYGENASES | CYTOCHROME-P450 | EVOLUTION | AZIDATION | NATURAL-PRODUCTS | IN-VIVO | BOND FUNCTIONALIZATION | AMIDATION | CHEMISTRY, MULTIDISCIPLINARY | Enzymes | Transformation | Haem | Amines | Directed evolution | Catalysts | Cytochrome P450 | Iron | Enantiomers | Organic chemistry | Chemical bonds | Coordination compounds | Cytochrome P450 monooxygenase
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 11/2014, Volume 136, Issue 44, pp. 15505 - 15508
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2018, Volume 118, Issue 2, pp. 229 - 250
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2013, Volume 11, Issue 1, pp. 56 - 70
Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been... 
Clinical practice guidelines | Anticoagulant | GRADE system | Bleeding | Venous thromboembolism | Cancer | DEEP-VEIN THROMBOSIS | SECONDARY PREVENTION | PERIOPERATIVE THROMBOPROPHYLAXIS | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | PERIPHERAL VASCULAR DISEASE | COMPRESSION STOCKINGS | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | LONG-TERM TREATMENT | VENA-CAVA FILTERS | UNFRACTIONATED HEPARIN | Recurrence | Humans | Antineoplastic Agents - therapeutic use | Venous Thromboembolism - drug therapy | Patient Selection | Fibrinolytic Agents - adverse effects | Neoplasms - complications | Venous Thromboembolism - prevention & control | Neoplasms - blood | Time Factors | Fibrinolytic Agents - therapeutic use | Venous Thromboembolism - diagnosis | Risk Assessment | Risk Factors | Cooperative Behavior | Benchmarking | Treatment Outcome | International Cooperation | Evidence-Based Medicine | Consensus | Vena Cava Filters | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Thrombolytic Therapy | Hemorrhage - chemically induced | Medical colleges | Aspirin | Glycosaminoglycans | Brain tumors | Leukemia | Oncology, Experimental | Practice guidelines (Medicine) | Laparoscopic surgery | Anticoagulants (Medicine) | Laparoscopy | Transplantation | Metastasis | Research | Pulmonary embolism | Blood circulation disorders | Cancer patients | Chemotherapy | Bone marrow | Adults | Drug therapy | Health aspects | Public health | Clinical medicine | Patients
Journal Article
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2013, Volume 11, Issue 1, pp. 71 - 80
Although long-term indwelling central venous catheters (CVCs) may lead to pulmonary embolism (PE) and loss of the CVC, there is lack of consensus on management... 
clinical practice guidelines | catheter | cancer | thrombosis | anticoagulant | GRADE system | Catheter | Clinical practice guidelines | Anticoagulant | Thrombosis | Cancer | LOW-DOSE WARFARIN | ADULT PATIENTS | RISK-FACTORS | ACCESS DEVICES | PREVENTION | LONG-TERM USE | CENTRAL VEIN CATHETER | MOLECULAR-WEIGHT HEPARIN | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | THROMBOEMBOLISM | HEMATOLOGY | Device Removal | Humans | Upper Extremity Deep Vein Thrombosis - prevention & control | Antineoplastic Agents - administration & dosage | Equipment Design | Patient Selection | Fibrinolytic Agents - adverse effects | Upper Extremity Deep Vein Thrombosis - diagnosis | Time Factors | Fibrinolytic Agents - therapeutic use | Catheterization, Central Venous - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Risk Assessment | Risk Factors | Cooperative Behavior | Benchmarking | Central Venous Catheters - adverse effects | Treatment Outcome | International Cooperation | Upper Extremity Deep Vein Thrombosis - etiology | Evidence-Based Medicine | Consensus | Neoplasms - drug therapy | Thrombolytic Therapy | Hemorrhage - chemically induced | Catheterization, Central Venous - instrumentation | Medical colleges | Care and treatment | Glycosaminoglycans | Oncology, Experimental | Practice guidelines (Medicine) | Valves | Transplantation | Anticoagulants (Medicine) | Research | Thrombolytic drugs | Pulmonary embolism | Cancer patients | Bone marrow | Drug therapy | Thromboembolism | Public health | Anticoagulants | Catheters
Journal Article
Nature chemistry, ISSN 1755-4330, 7/2017, Volume 9, Issue 7, pp. 629 - 634
C–H bonds are ubiquitous structural units of organic molecules; while these bonds are generally considered to be chemically inert, the recent emergence of methods for C... 
Journal Article
by Meade, T and Collins, R and Armitage, J and Parish, S and Barton, J and Bray, C and Wincott, E and Bowman, L and Clarke, R and Graham, I and Simpson, D and Warlow, C and Tobert, J and Musliner, T and Doll, R and Fox, K.M and Hill, C and Sandercock, P and Peto, R and Webster, J and Jamieson, J and Nixon, A and Lackie, S and Thompson, J and Brown, M and Blackwood, S and Morgan, M and Rhoden, W and Saeed, B and Houghton, M and Nicholson, A and Simpson, C and Hoburn, B and Cooper, I and Gallivan, A and Pickerell, E and Hancock, J and Watkinson, J and Burbridge, W and Kitchen, M and O'Leary, H and Verow, C and Meynell, L and Rollinson, L and Bain, S and Jones, A and Jewkes, C and Russon, C and Bateson, M and Gill, P and Stansbie, D and Bayly, G and Andrews, G and Halestrap, M and Meredith, J and Best, R and Appleyard, D and Wareing, H and Holmes, K and Holt, J and Kenyon, M and White, C and Khalifa, M and Newton, D and Wass, A and Watkinson, R and Creamer, J and Bethell, A and Butler, C and Washington, M and Weston, E and Machin, J and Cleaver, K and Wray, R and Sinclair, J and Van Aalst, A and Been, M and Mattu, R and Burke, A and Gill, L and Walton, E and Cowley, M and Robson, H and Graham, A and Rose, G and Kerr, M and Mallinson, J and Peascod, B and Scott, A and Donnelly, R and Gibson, T and Hannah, J and Henshaw, L and Margetts, M and Pearson, N and Frost, S and Murray, S and Marshall, A and Went, J and Simmonds, J and ... and unav and The SEARCH Collaborative Group and SEARCH Collaborative Grp and SEARCH Collaborative Group and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 359, Issue 8, pp. 789 - 799
A genomewide screen of patients with myopathy who were taking high-dose simvastatin (80 mg per day) showed a strong association between myopathy and variants... 
MEDICINE, GENERAL & INTERNAL | POLYMORPHISMS | EFFICACY | SAFETY | TRANSPORTING POLYPEPTIDE 1B1 | SIMVASTATIN | CYP3A4 | ASSOCIATION | ATORVASTATIN | Simvastatin - therapeutic use | Simvastatin - adverse effects | Humans | Middle Aged | Diabetes Mellitus - drug therapy | Genotype | Male | Risk | Genetic Markers | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Myocardial Infarction - drug therapy | Arterial Occlusive Diseases - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Aged | Myocardial Infarction - prevention & control | Polymorphism, Single Nucleotide | Chromosomes, Human, Pair 12 | Muscular Diseases - chemically induced | Muscular Diseases - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Complications and side effects | Analysis | Muscle diseases | Genetic aspects | Dosage and administration | Single nucleotide polymorphisms | Risk factors | Statins | Drug therapy | Kinases | Drug dosages | Cholesterol | Index Medicus | Abridged Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | Single Nucleotide | genetics | Arterial Occlusive Diseases | pharmacokinetics | Muscular Diseases | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Chromosomes | MEDICAL AND HEALTH SCIENCES | Human | drug therapy | chemically induced | Simvastatin | prevention & control | Diabetes Mellitus | Myocardial Infarction | Pair 12 | Organic Anion Transporters | adverse effects | therapeutic use | Polymorphism
Journal Article
Angewandte Chemie (International ed.), ISSN 1433-7851, 2019, Volume 58, Issue 51, pp. 18535 - 18539
Non‐heme iron halogenases are synthetically valuable biocatalysts that are capable of halogenating unactivated sp3‐hybridized carbon centers with high stereo‐... 
halogenases | C−H activation | non-heme iron enzymes | biocatalysis | directed evolution | Enzymes | Regioselectivity | Indole | Halogenation | Heme | Evolution | Iron | Biocatalysts | Substrates | Aliphatic compounds
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9753, pp. 1658 - 1669
Journal Article